FLT3 and cancer: Additionally, the IDH2 (isocitrate dehydrogenase 2) mutations could alter the cellular metabolism and epigenetic regulation mechanisms, which could lead to the development of an alternative oncogenic pathway that promotes the survival of cancer cells independent of FLT3 pathway, making these cells resistant to FLT3 inhibitors [59].